NYSE · REGN
Healthcare · Biotechnology
$818.77
Up+$109.12 (+13.33%)
Updated Oct 30, 2026, 11:49 PM
SID Score
6.7/10
Composite research score
Smart Money
54/100
Neutral
Price performance · REGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
REGN closed at $818.77 after 21 trading sessions, up 11.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $826.14 | $828.1899 | $811.63 | $818.77 | 789.29K |
| Oct 28, 2026 | $807.06 | $821.16 | $802.20 | $813.27 | 536.5K |
| Oct 27, 2026 | $807.67 | $816.14 | $804.05 | $816.10 | 726.15K |
| Oct 26, 2026 | $812.31 | $817.1699 | $796.61 | $807.67 | 423.96K |
| Oct 23, 2026 | $819.09 | $819.09 | $801.22 | $805.02 | 527.74K |
| Oct 22, 2026 | $809.01 | $825.52 | $800.00 | $819.09 | 852.59K |
| Oct 21, 2026 | $806.74 | $813.86 | $800.24 | $805.67 | 581.05K |
| Oct 20, 2026 | $793.85 | $807.86 | $789.69 | $807.48 | 623.4K |
| Oct 19, 2026 | $792.59 | $800.00 | $780.83 | $782.04 | 489.58K |
| Oct 16, 2026 | $803.01 | $805.675 | $787.32 | $790.74 | 653.73K |
| Oct 15, 2026 | $802.33 | $809.49 | $792.58 | $796.34 | 798.91K |
| Oct 14, 2026 | $758.16 | $781.84 | $755.21 | $778.36 | 879.09K |
| Oct 13, 2026 | $762.485 | $765.60 | $743.5666 | $753.12 | 629.55K |
| Oct 12, 2026 | $748.67 | $768.6581 | $744.96 | $762.81 | 618.29K |
| Oct 9, 2026 | $737.20 | $751.27 | $732.83 | $746.54 | 466.03K |
| Oct 8, 2026 | $742.12 | $744.50 | $723.647 | $739.57 | 500.3K |
| Oct 7, 2026 | $738.05 | $753.68 | $734.18 | $742.12 | 626.43K |
| Oct 6, 2026 | $734.61 | $740.51 | $727.155 | $738.72 | 615.06K |
| Oct 5, 2026 | $734.365 | $736.42 | $722.02 | $726.47 | 695.03K |
| Oct 2, 2026 | $740.50 | $742.50 | $729.1983 | $735.20 | 613.95K |
| Oct 1, 2026 | $766.53 | $777.43 | $726.02 | $734.81 | 1.04M |
The latest Smart Investors Daily articles mentioning REGN.
Company
Market Activity
Research & News
REGN research
Company profile and research snapshot.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Canaccord Genuity | Buy | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 19, 2026 | Piper Sandler | Overweight | — |
| Oct 15, 2026 | UBS | Buy | — |
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Aug 1, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.
Benzinga · Jul 31, 2026
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Yahoo · Jul 31, 2026
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
Benzinga · Jul 31, 2026
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning REGN.
